58 results about "Virus Binding" patented technology

The present invention relates to the field of detection of viruses, and in particular to detection of viruses using a liquid crystal assay format. In the present invention, virus binding in a detection region is identified by changes in liquid crystal orientation caused by virus binding independent orientation caused by any topography associated with the detection region.

The present invention relates to a method for detecting a target material in a sample, which method comprises the steps of: a) exposing a sample, expected to contain that target material, to at least two viruses which are capable of binding directly or indirectly with that target material so as to form a virally bound target material and to endow the virally bound target material with a distinctive property; and b) cultivating the product from stage a in the presence of an indicator material to which the viruses carried by the virally bound target material attach so as to cause the indicator material to adopt the distinctive property of the virally bound target material; and c) monitoring the presence or otherwise of virally attached indicator material. The invention also provides a kit for use in the method of the invention.

The present invention uses the replaseable biosensor chip technology as core, and uses the related MEMS system formed from microreactor and microflow cell to make determination of environment pollution. After the harmfule molecule (for example influenza virus or SARS virus) is combined on the functional chip, said polluted molecule can store the information, and can release it in specific environment, and its released information is directly propertional to the polluted extent, so that it can implement the determination of environmental pollution.

The instant disclosure provides norovirus-binding aptamers, compositions comprising such aptamers, and methods of using and producing such aptamers. The aptamers are useful, for example, for detecting the presence of norovirus in test samples, for capturing and/or concentrating norovirus from test samples, for evaluating the efficacy of therapeutic agents in patients diagnosed with a norovirus infection, and for evaluating the efficacy of norovirus vaccines.

The invention discloses a virus detector, which comprises an interdigital array microelectrode (1), a micro fluidic detection pool (2) and an impedance detection module (3); when a sample containing virus is injected into the micro fluidic detection pool (2), an antibody or other biological identification materials fixed on the surface of the interdigital array microelectrode (1) embedded in the micro fluidic detection pool (2) can be combined with virus, impedance change is generated, impedance measure is carried out through an impedance detection module (3), data processing is carried out by using a standard curve, so that bird flu virus content can be rapidly and quantitatively determined. The virus detector has the advantages of fast detection speed, convenient operation, quantitative analysis and on-site detection.

Compositions and methods are provided for the treatment or prevention of RSV disease by modulating RSV infection and immunity. In particular, amino acid sequences in the RSV G glycoprotein, containing the chemokine motif defined as C-X-X-X-C (or CX3C), are identified that are essential in causing RSV infection and disease. The chemokine motif is biologically active and participates in virus binding to and infection of susceptible cells. The prevention or treatment of RSV infection is achieved by interfering with the motif, such as by administering a vaccine in which the motif is altered or by administration or induction of blocking molecules that inhibit the biological activity of the motif.

Methods for obtaining modified proteins or virus with an intact native binding site and decreased antigenicity and modified proteins or virus obtainable by said methods are provided. The methods of protein or virus modification comprise masking with non-immunogenic molecules the protein or the virus surface, except for the protein or the virus binding site. Examples of modified proteins or virus that can be modified in accordance to the methods include polyclonal or monoclonal antibodies, modified replication-defective virus, hormones, and enterotoxins.

The invention discloses a cyclic peptide combined with an RBD site of novel coronavirus as well as a preparation method and application of the cyclic peptide, and particularly relates to a cyclic polypeptide molecule obtained through in-vitro amino acid side chain cyclization, amino acid point mutation and dimerization modification on the basis of an angiotensin converting enzyme 2 (ACE2) core sequence combined with the RBD of novel coronavirus. The cyclic polypeptide disclosed by the invention can be used for preparing a polypeptide drug with an SARS-CoV-2 virus inhibition effect, or used for preparing a detection reagent for detecting SARS-CoV-2, and a bioactive lead molecule with commercial value is provided for treatment and detection of SARS-CoV-2.

The subject invention provides materials and methods for improving animal resistance to infection by intestinal viruses. This is accomplished by interfering with intestinal virus uptake employing methods that (1) reduce virus binding to receptors in the intestinal lining; (2) introduce decoy receptors expressed in the mammary gland leading to decoy secretion in milk; (3) produce decoy receptors by a variety of protein synthesis methods to provide decoy receptors to non-genetically modified animals, including humans; and/or (4) administer a vector to a non-genetically modified animal which vector has been genetically modified to produce a decoy receptor.

The invention discloses a gel dressing for preventing and treating human papillomavirus infection. The gel dressing is prepared by taking a CP protein, carbomer, carboxylated chitosan, glycerol and Arabic gum as main raw materials, wherein the mass percentages of the raw materials are as follows: 0.01-0.1% of the CP protein, 0.1-1% of the carbomer, 0.1-1% of the carboxylated chitosan, 5-15% of theglycerol, 0.5-3% of the Arabic gum and the balance of water. According to the invention, the CP protein is used as a main effective component, and the whole CP protein is negatively charged, can be combined with HPV viruses to inactivate the HPV viruses, and has repair capability on damaged tissues. The invention also discloses an application of the gel dressing in preparing medicaments for preventing and treating human papillomavirus infection.

This invention teaches a novel treatment of patients infected with influenza virus in early stages of the disease, with liposomes called α-gal/SA liposomes, in order to decrease the infection period and decrease further complications by this disease. The treatment is based on inhalation of biodegradable liposomes that present two types of carbohydrate epitopes: α-Gal epitopes with the structure Galα1-3Galβ1-4(3)GlcNAc-R) and sialic acid (SA) epitopes. The treatment is based on the ability of influenza virus to bind to SA epitopes and on the binding of the natural anti-Gal antibody (the most abundant natural antibody in humans) to α-gal epitopes. Following inhalation of aerosolized α-gal/SA liposomes they land in the mucus lining the respiratory tract. The α-gal/SA liposomes bind influenza virus via SA epitopes interaction with hemagglutinin of the virus, thus they slow or prevent the progress of the influenza virus infection process. Binding of the natural anti-Gal antibody to α-gal epitopes on α-gal/SA liposomes causes complement mediated chemotactic recruitment of macrophages and dendritic cells which internalize via Fc/Fc receptor interaction the α-gal/SA liposomes and the influenza virus bound to them and destroy this virus. The recruited macrophages and dendritic cells further process the immunogenic peptides of the internalized virus, transported them to the regional lymph nodes and present these peptides for eliciting an effective protective immune response that ends the influenza virus infection in a period shorter than in untreated patients and prevents further complications in the respiratory system and in other parts of the body.

The invention provides a human angiotensin converting enzyme 2-based affinity polypeptide for the severe acute respiratory syndrome coronavirus 2, and relates to the technical field of biological materials. Key human angiotensin converting enzyme 2 amino acid residues of binding sites of human angiotensin converting enzyme 2 and the severe acute respiratory syndrome coronavirus 2 are extracted toreconstruct a peptide library, and the human angiotensin converting enzyme 2-based affinity polypeptide for the severe acute respiratory syndrome coronavirus 2 is obtained by screening; and then, a biological detection reagent is prepared from the affinity polypeptide, and thus, a new method is provided for detection of the severe acute respiratory syndrome coronavirus 2.

The invention relates to a polypeptide and a gold nano-antibody capable of targeting an HIV (human immunodeficiency virus) envelope protein gp120. The artificial antibody consists of gold nanoparticles and a section of designed polypeptide sequence. The prepared gold nano-antibody can enhance the binding strength of a drug to a target, namely, when the concentration of the virus gp120 in the bodyis very low, the binding strength can be maintained at a high level. At the same time, the gold nano-antibody has the characteristics of small particle size, excellent dispersibility, good stability and the like, can reach the parts which cannot be reached by common drugs, and can bind to viruses more strongly. Therefore, the artificial antibody has broad application prospects in the field of biomedicine.

The present invention relates to a method for treating cancer in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a Coxsackie B3 group virus or a modified form thereof, wherein the cells of the cancer express a heparan sulfate (HS) receptor on their surface and the virus binds to said HS receptor, enters and accumulates in the cancer cells, whereby at least some cancer cells undergo viral lysis.

The invention discloses a recombinant protein for detecting a hog cholera virus. The recombinant protein is encoded by a fusion gene which is formed by splicing a surface antigen single-chain antibody gene of anti-human red blood cell H and an envelop glycoprotein single-chain antibody gene of anti-hog cholera virus E2. The recombinant protein has a double-function characteristic, can be conjugated with the human red blood cell without agglutination and further conjugated with the hog cholera virus, and under the virus binding action, generates agglutination megascopically. The recombinant protein can be used for detecting the hog cholera virus, is simple in operation, high in flexibility and strong in specificity, and can meet the requirement of quickness, simpleness and convenience for use in the grass-root level field.

The present invention relates to the use of a phage blocking assay to determine unknown binding molecule present on or in the surface of a cell, a non-infectious moiety, a bacteria, a virus, or another pathogen. In particular embodiments, the invention relates to the identification of unknown receptors on a cell or virus involved in infection. Further, it relates to the use of said binding molecules, for example virus binding molecules or cellular receptors and binding members with binding specificity to said binding molecules, for example antibodies, in methods of therapy.

The invention discloses a GK-7 oligopeptide for resisting novel coronavirus infection. The amino acid sequence of the GK-7 oligopeptide is GKGDFRI. The invention further discloses a preparation methodand application of the GK-7 oligopeptide. The GK-7 oligopeptide is derived from human body protein, contains key residues of a virus-binding cell receptor, and is simple to prepare and good in clinical application prospect.

The invention is directed to the treatment of COVID-19 patients by administering to patients either infected by SARS-CoV-2 or presymptomatic for COVID-19 but at risk of severe morbidity and mortality due to potential COVID-19 infection. Such patients are given modified pectin, preferably modified citrus pectin, in an amount that may range from 2.5 or 5 on up to 10-25 grams per day, divided into two or three doses per day. The administration may be oral, by inhalation, intrabuccal or IV. The process may be combined with the administration of supportive agents like antivirals, anti-inflammatories, immune based inhibitors, vitamins, monoclonal and polyclonal anti-viral or viral binding antibodies.

The present invention provides humanized antibodies and antigen binding fragments thereof that bind to human poliovirus (PVR). The antibodies can be used to treat tumors or cancers.

The invention discloses a method for analyzing virus capture of a nanoprobe in a dark field microscope based on deep learning. The method comprises the following steps: (1) extracting a gold nanoprobebased on Opencv and designing a denoising model; (2) ResNet50 is a model design for judging the sandwich structure of the nanoprobe; and (3) performing real-time analysis and judgment on the dark field microscope imaging original image by using the trained ResNet50-based sandwich structure resolution model and the Opencv-based gold nanoparticle extraction denoising model. According to the method,background interference is effectively removed based on a gold nanoprobe extraction model of OpenCV, and a sandwich structure judgment model based on ResNet50 correctly recognizes a'silver nanoprobe-virus-gold nanoprobe 'sandwich structure formed by combining gold and silver double nanoprobes and viruses, so that the counting efficiency and accuracy of the nanoprobes in a dark field after capturing the viruses are guaranteed; therefore, the method has a real application value in target molecule and microorganism detection with the nanoparticles as signal probes and a dark-field microscope asa platform.